Interpreting long‐term response to rituximab in immune thrombocytopenia: Cohort construction, treatment attribution, and dynamic prognostication
HemaSphere · 2026-10 · 10 (10)
DOI: 10.1002/hem3.70519 ↗Kurz gefasst
Editorial in der Zeitschrift HemaSphere, online erschienen am 27.10.2026. Verfasst von Xin Zhou und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology The Second Qilu Hospital of Shandong University Jinan Shandong China. Die Arbeit nennt 7 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Department of Hematology The Second Qilu Hospital of Shandong University Jinan Shandong China.
- Department of Hematology, The Second Hospital of Shandong University Shandong Key Laboratory of Cancer Digital Medicine Jinan Shandong China.
- Institute of Biotherapy for Hematological Malignancies, Shandong University Jinan China.
ORCID-Profile: Xin Zhou, Ningning Shan
Zitieren
APA
Zhou, X., & Shan, N. (2026). Interpreting long‐term response to rituximab in immune thrombocytopenia: Cohort construction, treatment attribution, and dynamic prognostication. HemaSphere, 10(10). https://doi.org/10.1002/hem3.70519
Vancouver
Zhou X, Shan N. Interpreting long‐term response to rituximab in immune thrombocytopenia: Cohort construction, treatment attribution, and dynamic prognostication. HemaSphere. 2026;10(10). doi:10.1002/hem3.70519
BibTeX
@article{Zhou2026,
author = {Zhou, Xin and Shan, Ningning},
title = {Interpreting long‐term response to rituximab in immune thrombocytopenia: Cohort construction, treatment attribution, and dynamic prognostication},
journal = {HemaSphere},
year = {2026},
volume = {10},
number = {10},
doi = {10.1002/hem3.70519}
}
EUVIMED